The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R

Endocrine-Related Cancer

Volumn 13, Issue 2, 2006, Pages 535-540

  Gross, David J ^a   Munter, Gabriel ^a   Bitan, Menachem ^a   Siegal, Tali ^a   Gabizon, Alberto ^b   Weitzen, Ronny ^c   Merimsky, Ofer ^d   Ackerstein, Aliza ^a   Salmon, Asher ^a   Sella, Avishai ^e   Slavin, Shimon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ADRENAL CORTEX CARCINOMA; ADULT; ANOREXIA; ARTICLE; BLEEDING TENDENCY; CARCINOID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE TUMOR; FATIGUE; FEMALE; HUMAN; MALE; MENTAL DISEASE; NAUSEA; PHEOCHROMOCYTOMA; SUICIDE ATTEMPT; THYROID MEDULLARY CARCINOMA; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ENDOCRINE GLAND NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TREATMENT OUTCOME;

EID: 33745067446     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01124     Document Type: Article

References (23)

1. Adams J, Huang P & Patrick D 2002 A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis. Current Opinion in Chemical Biology 6 486-492.
2. Beppu K, Jaboine J, Merchant MS, Mackall CL & Thiele CJ 2004 Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. Journal of the National Cancer Institute 96 46-55.
3. Bottaro DP & Liotta LA 2003 Cancer: Out of air is not out of action. Nature 423 593-595.
4. Carr K, Yao JC, Rashid A, Yeung S-C, Szklaruk J, Baker J, Vauthy J-N, Curley S, Ellis L & Ajani JA 2004 A phase II trial of imatinib in patients with advanced carcinoid tumor. Journal of Clinical Oncology 22 4124.
5. Cohen MS, Hussain HB & Moley JF 2002 Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132 960-966; discussion 966-967.
6. Connolly BL & von Mehren M 2003 Pharmacotherapy of gastrointestinal stromal tumours. Expert Opinions in Pharmacotherapy 4 869-874.
7. Connolly EM, Gaffney E & Reynolds JV 2003 Gastrointestinal stromal tumours. British Journal of Surgery 90 1178-1186.
8. Druker BJ 2003 Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opinion in Pharmacotherapy 4 963-971.
9. Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM, Jr., Morton RF, Schild SE, Jett JR & Adjei AA 2005 A phase II trial of imatinib (STI571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Annals in Oncology 16 1811-1816.
10. Fletcher JA 2004 Role of KIT and platelet-derived growth factor receptors as oncoproteins. Seminars in Oncology 31 4-11.
11. Funa K, Papanicolaou V, Juhlin C, Rastad J, Akerstrom G. Heldin CH & Oberg K 1990 Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors. Cancer Research 50 748-753.
12. Gambacorti-Passerini C, Piazza R, Tornaghi L, Pilotti S & Pogliani E 2004 Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatment. Journal of the National Cancer Institute 96 1723-1724.
13. Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, Kris MG, Pizzo B, Tyson L, Dunne M et al. 2005 Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 103 2128-2131.
14. McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S & Fletcher JA 2005 Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. Journal of Clinical Oncology 23 866-873.
15. Matsuda R, Takahashi T, Nakamura S, Sekido Y, Nishida K, Seto M, Seito T, Sugiura T & Ariyoshi Y 1993 Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. American Journal of Pathology 142 339-346.
16. Modlin IM, Lye KD & Kidd M 2003 A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97 934-959.
17. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML. Scheibe DN, Snell GP, Zou H, Sang BC & Wilson KP 2004 Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. Journal of Biological Chemistry 279 31655-31663.
18. Oberg K 2003 Diagnosis and treatment of carcinoid tumors. Expert Reviews in Anticancer Therapy 3 863-877.
19. Papotti M, Olivero M, Volante M, Negro F, Prat M, Comoglio PM & DiRenzo MF 2000 Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocrine Pathology 11 19-30.
20. Skinner MA, Safford SD & Freemerman AJ 2003 RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571. Anticancer Research 23 3601-3606.
21. Timeus F, Crescenzio N, Valle P, Pistamiglio P, Piglione M, Garelli E, Ricotti E, Rocchi P, Strippoli P, Cordero di Montezemolo L et al. 1997 Stem cell factor suppresses apoptosis in neuroblastoma cell lines. Experimental Hematology 25 1253-1260.
22. Timeus F, Ricotti E, Crescenzio N, Garelli E, Doria A, Spinelli M, Ramenghi U & Basso G 2001 Flt-3 and its ligand are expressed in neural crest-derived tumors and promote survival and proliferation of their cell lines. Laboratory Investigations 81 1025-1037.
23. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA, Zerbini MC, Liberman B, Carlos Gomes G & Kirschner MA 2000 Adrenocortical carcinoma: clinical and laboratory observations. Cancer 88 711-736.